The Silent Killer: The Impact Of Kidney Disease On Patients And Their Caregivers. Unicyive...
Los Altos, CA --News Direct-- Unicycive Therapeutics, Inc.
By Julian Richard, Benzinga
Unicycive Therapeutics Inc (NASDAQ: UNCY)...
He Shoots And He Scores. Ardelyx (ARDX) Gains 78%. Happy New Year!
Ah yes, and Gains Come to the Patient, as the FDA Moves the Ardelyx Ball Further Along.
Can This Diabetes Drug Make you Smarter?
OKAY, maybe not make you smarter, but a new study out today says it may delay the onset of dementia - so...
Adding Unicycive (UNCY) $0.75 to the Watch List.
Similar to Ardlyx (ARDX) which we added to the Watch List last week, Unicycive (no we don't know how they pronounce it) which will call UNCY - is...
FDA Approval for Provention Bio (PRVB).
Re-cork the Champagne!
We were contemplating (dreaming) about an opening price over $12, and then a drift up...
Adding Ardelyx (ARDX) $1.57 to Watch List.
FDA Advisory Committee Says Go Forth Young Man!
While we hadn't previously owned Ardelyx, nor are they a...
Provention Bio (PRVB) Announces $125 Million Term Loan Facility with Hercules Capital
Don't think we've ever seen anything like this before. Most investors who prefer to invest post FDA approval, invest post FDA approval....
Provention (PRVB) Price Target $18.
Headline Says Downgrade, But That's Near 300% Higher From Here!
LIVE QUOTE
Adding Provention Bio (PRVB) $4.60 to 2022 Biotech Watch List.
This is in our 'Stocks we Hope to Double' Watch List.
LIVE QUOTE
Preventing Type I Diabetes. Here’s How Provention (PRVB) Works.
Here's How Provention's Treatment Works.
Interview With an Actual Provention Bio (PRVB) Clinical Trial Participant.
Latest article
We’re in Tampa for the Kentucky Derby.
GeoVax (GOVX), Sees a Little Volume.
Normally, we get a little nervous when one of the companies we...
Institutional Analyst Newsletter. Citius (CTXR), GeoVax (GOVX.
DERBY WEEKEND - WE'RE HEADED TO TAMPA!HAT'S ON, DRINK'S UPADDING CITIUS PHARMA (CTXR) $0.66, TO WATCHLISTUPDATING GEOVAX LABS (GOVX) $1.43OUR $26...
Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.
Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!
